Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.53 |
| ▸ | TEAD1 | P28347 | 7/20 | 0.51 |
| ▸ | PTPN1 | P18031 | 5/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.37 |
| ▸ | AR | P10275 | 1/20 | 0.37 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.37 |
| ▸ | MAOB | P27338 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | PPARG | P37231 | 2/20 | 0.36 |
| ▸ | PPARA | Q07869 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | RET | P07949 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12896348 | 1.00 | TSHR (0.53) | TSHRTEAD1PTPN1ALDH1A1HPGD | |
| SCHEMBL12896347 | 1.00 | TSHR (0.53) | TSHRTEAD1PTPN1ALDH1A1HPGD | |
| SCHEMBL12896387 | 0.89 | TSHR (0.44) | TSHRTEAD1PTPN1ALDH1A1HPGD | |
| SCHEMBL12896386 | 0.89 | TSHR (0.44) | TSHRTEAD1PTPN1ALDH1A1HPGD | |
| SCHEMBL12896392 | 0.86 | TEAD1 (0.54) | TSHRTEAD1PTPN1CYP19A1 | |
| SCHEMBL12896391 | 0.86 | TEAD1 (0.54) | TSHRTEAD1PTPN1CYP19A1 | |
| SCHEMBL12897055 | 0.84 | TEAD1 (0.44) | TSHRTEAD1PTPN1ALDH1A1HPGD | |
| SCHEMBL12897050 | 0.84 | TEAD1 (0.44) | TSHRTEAD1PTPN1ALDH1A1HPGD | |
| SCHEMBL12897747 | 0.82 | TEAD1 (0.43) | TSHRTEAD1PTPN1CYP19A1 | |
| SCHEMBL12897795 | 0.82 | TEAD1 (0.43) | TSHRTEAD1PTPN1CYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9149465-B2 | Isoxazolines as inhibitors of fatty acid amide hydrolase | INFINITY PHARMACEUTICALS, INC. (US) | 2015-10-06 | — | — | US | disclosed |
| US-9149465-B2 | Isoxazolines as inhibitors of fatty acid amide hydrolase | INFINITY PHARMACEUTICALS, INC. (US) | 2015-10-06 | — | — | US | disclosed |
| US-20120122679-A1 | MESOIONIC PESTICIDES | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 2012-05-17 | — | — | US | disclosed |
| EP-2300484-B1 | NOVEL CLASS OF SPIRO PIPERIDINES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | PFIZER (US) | 2011-12-14 | — | — | EP | disclosed |
| EP-2300484-B1 | NOVEL CLASS OF SPIRO PIPERIDINES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | PFIZER (US) | 2011-12-14 | — | — | EP | disclosed |
| EP-2300484-A1 | NOVEL CLASS OF SPIRO PIPERIDINES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | Pfizer Inc. (US) | 2011-03-30 | — | — | EP | disclosed |
| US-20110046160-A1 | Novel Class of Spiro Piperidines for the Treatment of Neurodegenerative Diseases | PFIZER, INC. | 2011-02-24 | — | — | US | disclosed |
| US-20110046160-A1 | Novel Class of Spiro Piperidines for the Treatment of Neurodegenerative Diseases | PFIZER, INC. | 2011-02-24 | — | — | US | disclosed |
| US-20110046160-A1 | Novel Class of Spiro Piperidines for the Treatment of Neurodegenerative Diseases | PFIZER, INC. | 2011-02-24 | — | — | US | disclosed |
| WO-2011017334-A2 | MESOIONIC PESTICIDES | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 2011-02-10 | — | — | WO | disclosed |
| US-20110028478-A1 | ISOXAZOLINES AS INHIBITORS OF FATTY ACID AMIDE HYDROLASE | INFINITY PHARMACEUTICALS, INC. (US) | 2011-02-03 | — | — | US | disclosed |
| US-20110028478-A1 | ISOXAZOLINES AS INHIBITORS OF FATTY ACID AMIDE HYDROLASE | INFINITY PHARMACEUTICALS, INC. (US) | 2011-02-03 | — | — | US | disclosed |
| WO-2009136350-A1 | NOVEL CLASS OF SPIRO PIPERIDINES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | PFIZER INC. (US) | 2009-11-12 | — | — | WO | disclosed |
| WO-2009136350-A1 | NOVEL CLASS OF SPIRO PIPERIDINES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | PFIZER INC. (US) | 2009-11-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110028478-A1 | ISOXAZOLINES AS INHIBITORS OF FATTY ACID AMIDE HYDROLASE | FAAH, FAAH2, HRH2 | TSHR 1401/4885TEAD1 2965/4885PTPN1 3150/4885 |
| US-20120122679-A1 | MESOIONIC PESTICIDES | CHRM2, CHRM5, CHRM1 | TSHR 440/4885TEAD1 4521/4885PTPN1 218/4885 |
| US-20110046160-A1 | Novel Class of Spiro Piperidines for the Treatment of Neurodegenerative Diseases | SNCA, PARK7, HTT | TSHR 2618/4885TEAD1 831/4885PTPN1 2952/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.